Coeptis Therapeutics Holdings Inc (NASDAQ: COEP)’s stock price has increased by 48.59 compared to its previous closing price of 0.14. However, the company has seen a 19.14% increase in its stock price over the last five trading sessions. prnewswire.com reported 2024-12-26 that Coeptis Aims to Bring AI Innovation in Biotechnology and Technology WEXFORD, Pa., Dec. 26, 2024 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company specializing in innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, proudly announces the completion of its acquisition of the NexGenAI Affiliates Network platform alongside the official launch of Coeptis Technologies.
Is It Worth Investing in Coeptis Therapeutics Holdings Inc (NASDAQ: COEP) Right Now?
Additionally, the 36-month beta value for COEP is -0.87. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for COEP is 29.57M and currently, short sellers hold a 1.37% ratio of that float. The average trading volume of COEP on December 26, 2024 was 511.23K shares.
COEP’s Market Performance
COEP stock saw an increase of 19.14% in the past week, with a monthly gain of 6.84% and a quarterly increase of 30.17%. The volatility ratio for the week is 19.57%, and the volatility levels for the last 30 days are 13.30% for Coeptis Therapeutics Holdings Inc (COEP). The simple moving average for the last 20 days is 14.53% for COEP stock, with a simple moving average of -16.41% for the last 200 days.
COEP Trading at 7.81% from the 50-Day Moving Average
After a stumble in the market that brought COEP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.75% of loss for the given period.
Volatility was left at 13.30%, however, over the last 30 days, the volatility rate increased by 19.57%, as shares surge +9.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.02% upper at present.
During the last 5 trading sessions, COEP rose by +19.20%, which changed the moving average for the period of 200-days by -50.33% in comparison to the 20-day moving average, which settled at $0.1842. In addition, Coeptis Therapeutics Holdings Inc saw -73.08% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at COEP starting from Cogley Brian, who purchase 5,000 shares at the price of $0.67 back on Jan 10 ’24. After this action, Cogley Brian now owns 30,000 shares of Coeptis Therapeutics Holdings Inc, valued at $3,350 using the latest closing price.
DeSilva Tara, the Director of Coeptis Therapeutics Holdings Inc, purchase 2,266 shares at $0.58 during a trade that took place back on Jan 12 ’24, which means that DeSilva Tara is holding 32,266 shares at $1,305 based on the most recent closing price.
Stock Fundamentals for COEP
Current profitability levels for the company are sitting at:
- -7.5 for the present operating margin
- 0.21 for the gross margin
The net margin for Coeptis Therapeutics Holdings Inc stands at -7.74. The total capital return value is set at -2.04. Equity return is now at value -205.37, with -127.52 for asset returns.
Based on Coeptis Therapeutics Holdings Inc (COEP), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at -4.05. The debt to equity ratio resting at 0.35. The interest coverage ratio of the stock is -33.98.
Currently, EBITDA for the company is -20.16 million with net debt to EBITDA at -0.06. When we switch over and look at the enterprise to sales, we see a ratio of 6.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.40.
Conclusion
In conclusion, Coeptis Therapeutics Holdings Inc (COEP) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
